In one of the biggest breakthroughs in schizophrenia research in recent times, Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia. The study published today in Molecular Psychiatry has the potential to transform global schizophrenia research and open new avenues for developing targeted immune cell therapies.
One in every 100 Australians lives with schizophrenia. No single cause of schizophrenia has been identified, and this has prevented the development of a cure. The current treatments for schizophrenia are designed to suppress symptoms rather than target underlying causes of the disorder. These drugs only partially relieve symptoms and can produce unwanted side effects.
To recognise the significance of this discovery Professor Shannon Weickert says you first need to understand most scientists have had a long held belief that immune cells were independent from the brain pathology in psychotic illnesses.
“In our study, we challenged this assumption that immune cells were independent of the brain in psychiatric illness and made an exciting discovery. We identified immune cells as a new player in the brain pathology of schizophrenia,” said Professor Shannon Weickert.
Current schizophrenia research has focused on the status of three brain cells: the neurons; the glial cells, which support the neurons; and the endothelial cells, which coat the blood vessels. Employing new molecular techniques allowed Professor Shannon Weickert and her team to identify the presence of a fourth cell, the macrophage, a type of immune cell in the brain tissue of people with schizophrenia who show high levels of inflammation.
Professor Shannon Weickert said immune cells have previously been ignored as they had long been viewed simply as travelers just thought to be passing by, undertaking surveillance work. They have never been a suspect until now.
“To find immune cells along the blood brain barrier in increased amounts in people with schizophrenia is an exciting discovery. It suggests immune cells themselves may be producing these inflammatory signals in the brains of people living with schizophrenia,” said Professor Shannon Weickert.
“We have observed in people with schizophrenia, the glial cells, one of the local residents, become inflamed and produce distress signals which change the status of the endothelial cells.
“We think this may cause the endothelial cells to extend sticky tentacles, so when the immune cells travel by some are captured. These cells may transmigrate across the blood brain barrier entering the brain in greater amounts in some people with schizophrenia compared to people without the disorder.”
This discovery shows that specific immune cells are in the brains of some people with schizophrenia in close enough proximity to the neurons to do damage.
Professor Peter Schofield, CEO of NeuRA said this innovative new research has the ability to alter the way in which we may be able to diagnose and treat schizophrenia.
“This breakthrough demonstrates the value of the NSW Government’s support for Professor Shannon Weickert as NSW Chair of Schizophrenia Research, which has delivered new insights that the community seeks,” said Professor Schofield.
Professor Shannon Weickert is encouraging a cross-collaborative approach between neuroscientists and immunologists globally, to work together to develop treatments targeting this abnormal immune pathology of schizophrenia.
“This opens whole new avenues for therapy, because it suggests that the pathology of schizophrenia could be within the immune cells and the immune cells could be contributing to the symptoms of schizophrenia,” said Professor Shannon Weickert.
Professor Shannon Weickert is uniquely motivated in her work, with her twin-brother being diagnosed with schizophrenia when he was 17 years old.
Learn more: Schizophrenia breakthrough
The Latest on: Schizophrenia
via Google News
The Latest on: Schizophrenia
- Long-term medication for schizophrenia is safeon January 10, 2020 at 6:57 am
Researchers at Karolinska Institutet in Sweden and their colleagues in Germany, the USA and Finland have studied the safety of very long-term antipsychotic therapy for schizophrenia. According to the ...
- Protein expression of prenyltransferase subunits in postmortem schizophrenia dorsolateral prefrontal cortexon January 10, 2020 at 3:50 am
The pathophysiology of schizophrenia includes altered neurotransmission, dysregulated intracellular signaling pathway activity, and abnormal dendritic morphology that contribute to deficits of ...
- Childhood exposure to dogs associated with less risk of schizophrenia later in lifeon January 9, 2020 at 8:55 pm
And results suggest that the earlier in life that exposure to dogs occurs the better. The study, "Exposure to Household Pet Cats and Dogs in Childhood and Risk of Subsequent Diagnosis of Schizophrenia ...
- A Blind Refugee With Schizophrenia Was In Detention For The Entire 2010s. He Just Won A Huge Court Case.on January 9, 2020 at 11:06 am
A 36-year-old Tamil refugee and torture survivor who is legally blind, and has schizophrenia and dementia, has been held in immigration detention for an entire decade by Australia. And he remains ...
- Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDAon January 9, 2020 at 3:00 am
Newron is developing Evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. In May 2019, the FDA requested that Newron complete ...
- Some Caplyta Results in Schizophrenia Reach Printon January 8, 2020 at 12:57 pm
The schizophrenia drug lumateperone (Caplyta) improved psychotic symptoms versus placebo in one of the two randomized phase III trials leading up its recent FDA approval. Among 435 adults with ...
- Mirtazapine Recall; Air Pollution & Schizophreniaon January 8, 2020 at 12:23 pm
Aurobindo Pharma is recalling one lot of generic mirtazapine, for a labelling error incorrectly listing 15 mg tablets as 7.5 mg.
- Does the air we breathe influence our schizophrenia risk?on January 8, 2020 at 9:10 am
Schizophrenia affects millions of people around the world and is a chief contributor to disability. Researchers are still working to uncover all the risk factors that could facilitate the development ...
- Air Pollution in Childhood Tied to Greater Schizophrenia Riskon January 8, 2020 at 6:13 am
A new Danish study shows that individuals who were exposed to a high level of air pollution during childhood are at greater risk of developing schizophrenia. The findings are published in the ...
via Bing News